Lineage Cell Therapeutics (LCTX) Receivables - Net (2016 - 2025)
Historic Receivables - Net for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to $127000.0.
- Lineage Cell Therapeutics' Receivables - Net fell 6864.2% to $127000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $127000.0, marking a year-over-year decrease of 6864.2%. This contributed to the annual value of $638000.0 for FY2024, which is 1436.24% down from last year.
- Lineage Cell Therapeutics' Receivables - Net amounted to $127000.0 in Q3 2025, which was down 6864.2% from $256000.0 recorded in Q2 2025.
- Lineage Cell Therapeutics' Receivables - Net's 5-year high stood at $50.8 million during Q4 2021, with a 5-year trough of $77000.0 in Q1 2024.
- Moreover, its 5-year median value for Receivables - Net was $326000.0 (2021), whereas its average is $3.1 million.
- Within the past 5 years, the most significant YoY rise in Lineage Cell Therapeutics' Receivables - Net was 127090000.0% (2021), while the steepest drop was 9954.57% (2021).
- Lineage Cell Therapeutics' Receivables - Net (Quarter) stood at $50.8 million in 2021, then plummeted by 99.41% to $300000.0 in 2022, then surged by 148.33% to $745000.0 in 2023, then fell by 14.36% to $638000.0 in 2024, then plummeted by 80.09% to $127000.0 in 2025.
- Its last three reported values are $127000.0 in Q3 2025, $256000.0 for Q2 2025, and $213000.0 during Q1 2025.